In This Article
When most people think of GLP-1 medications, they think "weight loss." But one of the most exciting stories in modern medicine isn't about weight at all — it's about what these medications are doing for the heart, kidneys, liver, and potentially the brain.
The SELECT Trial: A Landmark Result
The game-changer was the SELECT trial — over 17,600 adults with established heart disease and overweight or obesity (without diabetes), tracked for more than three years.
Headline result: Semaglutide reduced major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20%. This made Wegovy the first anti-obesity medication ever approved for cardioprotection.
For the full picture of how semaglutide and tirzepatide work at the cellular level, our article on how GLP-1 medications work explains the underlying biology.
How GLP-1s Protect the Heart
The cardiovascular benefits go beyond what weight loss alone would explain:
Anti-inflammatory effects: GLP-1 medications reduce systemic inflammation markers — C-reactive protein, interleukin-6 — that damage blood vessels and promote plaque.
Improved endothelial function: They help keep arteries flexible and reduce atherosclerosis progression.
Blood pressure reduction: Consistent 3–6 mmHg systolic drops — clinically meaningful over time.
Better lipid profiles: Decreased triglycerides and modest LDL improvements.
Reduced visceral fat: Beyond visible fat, GLP-1s reduce the metabolically dangerous fat packed around organs.
Kidney Protection: The FLOW Trial
The FLOW trial found semaglutide significantly slowed kidney disease progression in patients with type 2 diabetes and chronic kidney disease — so clearly that the trial was stopped early because benefits were undeniable.
Liver Disease Benefits
NAFLD and MASH affect an estimated 80–100 million Americans. GLP-1 medications have shown remarkable results reducing liver fat and inflammation. The FDA expanded Wegovy's indication to include MASH treatment in adults with moderate to advanced liver scarring.
The Brain Connection
GLP-1 receptors are found throughout the central nervous system. Epidemiological studies show patients on GLP-1 agonists have lower rates of dementia and Parkinson's. Clinical trials testing semaglutide for Alzheimer's are underway. It's early — but the signals are fascinating.
More Than Weight Loss Drugs
GLP-1 receptor agonists are emerging as something bigger than weight loss medications — they appear to address systemic metabolic dysfunction connecting obesity to cardiovascular disease, kidney disease, liver disease, and potentially neurodegeneration.
That doesn't mean everyone should take one. They have side effects, they're not cheap (though costs are coming down), and they're not for every patient. But for those who are candidates, the risk-benefit equation has shifted dramatically.
If you're wondering whether the weight loss itself is worth pursuing, consider this alongside our comparison of semaglutide vs tirzepatide to understand which medication might align with your health goals.
Want to learn more about GLP-1 treatment options? Compare telehealth providers offering weight loss and cardiometabolic health programs.
Compare Top Providers →